Let me add my armchair opinion for the sake of discussion.
Yes, those prices are still unreasonable.
$10B or $5B market cap would be ridiculous for a company that still needs to fund and conduct a Phase 3, and then still needs to market and sell the drug. We have ZERO marketing experience, and ZERO sales channels. We will probably find a partner for this who already has these in place. Once all that is said and done (3-5 years out?), maybe $1B+ market cap would be reasonable?
The assumes no set backs along the way. Also does not take into account anything with hemangioblast program or myoblast (lol) program, or European/Asian side of things.
News 
Market Data 
Discover 
